Tofacitinib

Tofacitinib (INN) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer. Tofacitinib is marketed as Xeljanz and Jakvinus.

It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries.